XML 21 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814
Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)
12 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expenses $ 1,018,000 $ 500,000
Luoxis Diagnostics [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized expense at March 31, 2015 $ 0 0
Weighted average remaining years to vest 0 years  
Vyrix Pharmaceuticals [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized expense at March 31, 2015 $ 0 0
Weighted average remaining years to vest 0 years  
Stock Options [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expenses $ 27,000  
Research and Development Expense [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expenses 427,000 206,000
Research and Development Expense [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expenses 92,000 38,000
General and Administrative Expense [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expenses 316,000 152,000
General and Administrative Expense [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expenses $ 183,000 $ 104,000